Journal of Mind and Medical Sciences
Volume 7

Issue 1

Article 19

2020

Duodenal carcinoid tumour – a case report
Vasile Negrean
IULIU HAȚIEGANU UNIVERSITY OF MEDECINE AND PHARMACY, 4TH MEDICAL DEPARTMENT, CLUJ
NAPOCA, ROMANIA

Cristina Buchman
PROF. DR. ION CHIRICUȚĂ INSTITUTE OF ONCOLOGY, CLUJ NAPOCA, ROMANIA,

Mirela Georgiana Perne
IULIU HAȚIEGANU UNIVERSITY OF MEDECINE AND PHARMACY, 4TH MEDICAL DEPARTMENT, CLUJ
NAPOCA, ROMANIA

Mircea Milaciu
IULIU HAȚIEGANU UNIVERSITY OF MEDECINE AND PHARMACY, 4TH MEDICAL DEPARTMENT, CLUJ
NAPOCA, ROMANIA

Iacob Domsa
UNIVERSITY HOSPITAL CF, CLUJ-NAPOCA

See next page for additional authors
Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Gastroenterology Commons, Oncology Commons, and the Surgery Commons

Recommended Citation
Negrean, Vasile; Buchman, Cristina; Perne, Mirela Georgiana; Milaciu, Mircea; Domsa, Iacob; Alexescu,
Teodora Gabriela; Para, Ioana; and Orasan, Olga Hilda (2020) "Duodenal carcinoid tumour – a case report,"
Journal of Mind and Medical Sciences: Vol. 7 : Iss. 1 , Article 19.
DOI: 10.22543/7674.71.P114118
Available at: https://scholar.valpo.edu/jmms/vol7/iss1/19

This Case Presentation is brought to you for free and open access by ValpoScholar. It has been accepted for
inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more
information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Duodenal carcinoid tumour – a case report
Authors
Vasile Negrean, Cristina Buchman, Mirela Georgiana Perne, Mircea Milaciu, Iacob Domsa, Teodora
Gabriela Alexescu, Ioana Para, and Olga Hilda Orasan

This case presentation is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol7/
iss1/19

Journal of Mind and Medical Sciences

https://scholar.valpo.edu/jmms/
https://proscholar.org/jmms/
ISSN: 2392-7674

Duodenal carcinoid tumour – a case report
Vasile Negrean 1, Cristina Buchman 2, Mirela Georgiana Perne 1, Mircea Milaciu 1,
Iacob Domsa3, Teodora Gabriela Alexescu 1, Ioana Para1, Olga Hilda Orasan 1
1

I ULIU H AȚIEGANU U NIVERSITY OF M EDECINE AND PHARMACY, 4 TH MEDICAL DEPARTMENT, C LUJ N APOCA, ROMANIA

2

PROF. D R. ION C HIRICUȚĂ I NSTITUTE OF O NCOLOGY, CLUJ N APOCA, ROMANIA,

3

UNIVERSITY H OSPITAL CF, C LUJ -N APOCA

ABST RACT

Duodenal carcinoids are rare tumours of the small intestine with
heterogenous clinical and pathological characteristics. The long -term
prognosis is very good if discovered in the early stages. We present
the case of a patient with a non-functional duodenal carcinoid tumour
discovered incidentally during an upper gastrointestinal endoscopy.
The diagnosis was confirmed through immunohistochemistry.
Treatment consisted of the endoscopic resection of the tumour and
the surveillance of the patient for the following 2 years, with no signs
of recurrence. We have conducted a literature review regarding the
clinical manifestations, diagnosis, treatment, and follow -up of
patients with this type of tumours.

Introduction
Carcinoid tumours arise from enterochromaffin cells
of the aerodigestive tract. They are also known as low or
intermediate grade well-differentiated neuroendocrine
tumours (NETs). The incidence rates of carcinoid tumours
has risen over time from 1.09:100000 (1973) to
6.98:100000 (2012). This increase is partly explained by
increased accessibility to endoscopic procedures and
imaging techniques, particularly computed tomography
(CT), which allow early detection in asymptomatic
patients [1].
Carcinoid tumours with a primarily duodenal
location represent less than 2% of the total number of
carcinoid gastro-intestinal tumours, accounting for the
lack of available data regarding these tumours in the
literature [2].

Case Report
We present the case of a 54-year-old male patient with
a history of gastro-esophageal reflux disease (GERD)
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treated with prokinetic and proton pump inhibitor (PPI)
therapy, returning for a routine follow-up consultation.
Because the patient was still presenting persistent
heartburn and bitter taste in the morning despite optimal
medical treatment, we decided to perform an upper
gastrointestinal endoscopy (UGE).
The UGE revealed a 5 mm sessile polyp on the
posterior wall of the duodenal bulb (Figure 1), followed
by endoscopic polypectomy. The histopathological
examination revealed several small solid nests on the
lamina propria. These had uniform appearance, were well
delineated, and consisted of round cells with granular
eosinophilic cytoplasm in moderate quantities, as well as
round normal and hyperchromatic nuclei, with no
significant atypia, with an appearance highly
suggestive of a neuroendocrine tumour (Figure 2).
Immunohistochemical staining (IHC) tested negative for
CKAE1/AE3 and positive for chromogranin (Figure 3)
and CD56, with a KI-67% index less than 2%. These
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results confirmed the diagnosis of a well-differentiated
(G1) duodenal neuroendocrine tumour.

Figure. 1. Upper gastrointestinal endoscopy showing
the 5 mm sessile polyp on the posterior wall of the
duodenal bulb.

Figure 2. Microscopic examination of the resected
piece, H&E, x10. Solid nests of neuroendocrine cells
in the duodenal lamina propria.

(gastrin, somatostatin, urinary 5-hydroxyindoleacetic acid
(5-HIAA) is only recommended when functional
syndromes are present, the most common being ZollingerEllison (ZES) syndrome and carcinoid syndrome [3].
A contrast CT scan of the abdomen and pelvis was
performed which did not reveal any other tumours nor
regional or distant lymph node involvement.
The patient’s final diagnosis was that of a well
differentiated (G1) duodenal neuroendocrine tumour pT1
cN0M0 and gastro-esophageal reflux disease (GERD).
The treatment recommended for GERD was PPI
therapy, while the treatment recommended for the
carcinoid tumour following its resection was periodic
surveillance. The follow-up of the patient was conducted
according to the ENETS guideline at 6 months, 1 year,
and 2 years [3]. Both biological and endoscopic followups were conducted, without revealing any signs of
recurrence.
We appreciate that the medium and long-term prognosis
is favourable, considering the small size of the primary
tumour (5 mm), its location in the duodenal mucosa, the
normal values of chromogranin A, the high degree of
differentiation (G1), the complete endoscopic resection, the
absence of liver metastases, and the favourable evolution
during the first two years of follow-up.
The case we are presenting is one of the few reported
in the literature of non-secreting NETs located in the
duodenum, discovered accidentally and very early on.
Jayarama et al. reported on the incidental discovery of
two synchronous carcinoid tumours – one gastric and one
duodenal [4]. There are two other reported cases of
duodenal NETs discovered incidentally during a routine
endoscopic examination [5, 6].
Several observational studies have characterized these
tumours. The largest study included 59 patients with
duodenal carcinoid tumours, of which only 39 were nonsecreting [7]. Considering the heterogeneity of these
tumours as well as the small number of studies available,
at this time we cannot draw precise conclusions regarding
the biological behaviour of well-differentiated, nonperiampullary, non-secreting duodenal neuroendocrine
tumours, as in the case of our patient.

Discussions

Figure 3. Immunohistochemical staining, x20.
Tumour cells diffusely positive for chromogranin
(x20).
The serum concentration of chromogranin A (CrA)
was within normal limits, with a value of 19.160 ng/ml.
According to the consensus published by ENETS, the
determination of other specific biological markers

Carcinoid tumours are a heterogenous group of
tumours with varying behaviours depending on their
location [8]. They are most frequently located in the
gastro-intestinal (55%) and bronchopulmonary tracts
(30%). Within the gastro-intestinal tract, the most
frequent location is the small intestine (45%), followed by
the appendix, colon, and stomach [2]. Although carcinoid
tumours are relatively rare, they are the most frequent
malignant tumours of the small intestine (44%). Tumours
with a primarily duodenal location represent less than 2%
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of the total number of well-differentiated gastro-intestinal
neuroendocrine tumours. These are usually solitary
lesions of small dimensions – 75% being under 2 cm.
They are most frequently located in the first and second
part of the duodenum (approximately 90%) [9].
Periampullary tumours are a special category, as studies
have shown that they exhibit a different behaviour,
leading some authors to suggest they be considered a
separate entity [3].
There are five clinico-pathological types of duodenal
neuroendocrine tumours described in the literature. In
order
of
frequency,
these
are:
gastrinomas,
somatostatinomas, non-functional tumours, gangliocytic
paragangliomas, and poorly differentiated tumours [10].
Most duodenal neuroendocrine tumours are restricted to
the mucosa and submucosa. However, 40-60% of cases
present regional lymph node involvement, while
metastatic disease is present in approximately 10% of
cases, with the most frequent metastatic site being the
liver [3,10].
Usually, the clinical presentation is non-specific. The
most commonly described symptoms are abdominal pain,
nausea, vomiting, and diarrhea. Obstructive jaundice may
appear in the case of periampullary tumours. A small
proportion of patients present functional syndromes such
as Zollinger-Ellison syndrome (ZES) or carcinoid
syndrome. ZES associated with duodenal NETs may
appear in relation to both sporadic tumours as well as part
of the MEN1 syndrome, in which case there are usually
multiple lesions. The carcinoid syndrome appears almost
exclusively in the case of metastatic disease [10]. Only
one case has been described in the literature referencing
the presence of carcinoid syndrome in the absence of
metastases [11].
The diagnosis is established through histopathological
and
immunohistochemical
(IHC)
examinations.
Chromogranin, synaptophysin, PGP 9.5, and/or CD56 are
the most sensitive and specific markers in the diagnosis of
neuroendocrine tumours [12]. Studies show that 75-100%
of duodenal carcinoids test positive for CrA, 80-100% for
NSE, and 91% for Leu-7 [13,14]. In general, the most
sensitive methods for locating neuroendocrine tumours
are CT, magnetic resonance imaging (MRI), and
somatostatin receptor scintigraphy (SRS). However, in the
case of duodenal tumours, these methods are not as
specific, considering that >75% of these tumours are
under 1 cm [3]. Studies indicate that conventional
imaging techniques detect <15% of tumours <1 cm [2],
while SRS approximately 50% [15]. In order to identify
the primary tumour, upper gastrointestinal endoscopy
remains the most sensitive method, complemented with
endoscopic ultrasound when possible, in order to assess
local extension. For complete staging, spiral CT/MRI or
SRS are recommended [3].
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Usually, CrA and urinary 5-HIAA are measured in
order to monitor carcinoid tumours. However, 5-HIAA is
only specific to serotonin producing tumours, so that its
measurement is useful only if carcinoid syndrome is
present or if IHC staining detects the presence of
serotonin [16]. Routine CrA measurement is
recommended for all patients with NETs, regardless of
their location [17]. High values appear in 56-100% of
duodenal neuroendocrine tumours and they are correlated
with the response to treatment [18].
The four main prognostic factors are: tumour stage,
grade, resection margins, and chromogranin value. The 5year survival rate is 80-85% for localized disease, 65-75%
for locally advanced disease, and 20-40% for metastatic
disease [9].
In order to determine tumour grade, the assessment of
the mitotic count/10HPF and/or ki-67 index through IHC
is necessary [14].
Usually, the treatment is curative. The endoscopic
resection is considered sufficient for small tumours
(<1cm). There is no consensus regarding intermediary
tumours (1-2 cm), with some authors recommending
surgery and others recommending endoscopic resection.
More studies are needed in order to standardize treatment
procedures [2,19]. Tumours larger than 2 cm are treated
exclusively by surgery. In the case of metastatic disease,
the resection of the primary tumour along with the local
treatment of metastases (surgery, ablation) is common
practice when possible [3,10]. Surgical excision is
preferred for periampullary tumours, regardless of tumour
size, as studies indicate that the presence of metastases is
not correlated with the size of the primary tumour in these
cases [20-22].
Systemic therapy applies only to the metastatic
disease, when local treatment of the metastases is not
possible. This includes somatostatin analogues and
peptide
receptor
radionuclide
therapy,
while
chemotherapy is used only for poorly differentiated
tumours. Symptomatic treatment is recommended
depending on the functional syndrome present in
secreting tumours [23].

Highlights
✓

✓

Primary duodenal carcinoid tumours represent a
heterogenous group of rare well-differentiated
neuroendocrine tumours of the gastro-intestinal tract;
In the past years, there has been an increase in the
incidence of these tumours, partly explained by more
frequent detection by upper gastrointestinal
endoscopy, which allows for an early diagnosis and a
better prognosis;
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Conclusions
The incidence of duodenal carcinoid tumours has risen
over time due to increased detection by upper
gastrointestinal endoscopy, which allows for an early
diagnosis, in an asymptomatic stage. Reporting these
cases is important in order to establish the most
appropriate management and follow-up for these patients,
especially for those with tumours of 1-2 cm.
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